Navigation Links
Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis

PALO ALTO, Calif., May 17, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved 50% enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To date the trial has had no Severe Adverse Effect (SAE) reported.

The Phase I open label clinical research trial for KOA, registered with the U.S. National Institutes of Health (NIH) under number NCT01809769 (click here to view), tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPC in order to reduce inflammation and regenerate damaged joint tissues. This trial is conducted at Shanghai Renji Hospital, one of the largest teaching hospitals in China.

"This patient enrollment achievement in our clinical trial is an exciting milestone for CBMG. We anticipate that enrollment will continue to move quickly and the study is on schedule to complete its Phase I clinical trial," said Dr. William Cao , President of Cellular Biomedicine Group.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit:

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Jeff Ramson 
Investor Relations
ProActive Capital Group
+1 646-863-6341

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064

SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
2. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
3. Proteins shine a brighter light on cellular processes
4. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
5. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
6. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
7. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
8. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
9. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
10. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
11. Cellular Therapy and Cord Blood 2013 Market Report
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
(Date:11/24/2015)... INCLINE VILLAGE, Nev. , Nov. 24, 2015  PDL ... John P. McLaughlin , the company,s president and chief ... Piper Jaffray Healthcare Conference next week in New ... and will occur on Tuesday, December 1, 2015 at 9:30 ... and Presentations." Please connect to the website at least 15 ...
(Date:11/24/2015)... ... , ... Whitehouse Laboratories is pleased to announce that it has completed construction ... dedicated to basic USP 61, USP 62 and USP 51 testing specific to raw ... and micro testing performed by one supplier. Management has formally announced that ...
(Date:11/23/2015)... , Nov. 24, 2015 Women with a certain ... exams face a higher risk of lung cancer than men ... next week at the annual meeting of the Radiological Society ... --> --> Lung nodules are ... as solid or subsolid based on their appearance on CT. ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)... , October 29, 2015 ... biometric authentication company focused on the growing mobile ... wallet announces that StackCommerce, a leading marketplace to ... featuring the Wocket® smart wallet on StackSocial for ... ) ("NXT-ID" or the "Company"), a biometric authentication ...
Breaking Biology News(10 mins):